JSC “Grindeks” informs that it has received over 70 offers concerning possible
further cooperation during the participation in the industry exhibition “CPhI
Worldwide 2009”, which has taken place from 13th till 15th of October in
Madrid, the capital of Spain.
Chairman of the board of „Grindeks”, Janis Romanovskis: „It is still too early
to talk about new cooperation partners - interests have to be mutually
evaluated, provisions have to be precised, and only then can a decision be
adopted. The pharmaceutical business is complicated, time-consuming and
strictly regulated - sometimes several years can pass from negotiations till
real cooperation.”
At the exhibition “Grindeks” has been presented with wide range of service
offers in the research, development, manufacture, registration and sales
domains. The participation in this, as well as other exhibitions, is
significant, not only in order to meet existing cooperation partners, but also
to present one's own company and products on a global basis, to create new
business contacts, as well as to find out about the development tendencies,
latest inventions and technologies. In general, approximately 90 meetings have
been organized at the “Grindeks” booth” during the exhibition.
Chairman of the board of „Grindeks”, Janis Romanovskis: „During previous year,
when we have taken part in the „CPhI” exhibition with our booth, it already has
become sure for us, that we can compete at the global pharmaceutical market as
a reliable, stable and qualitative partner. In order to minimize the influence
of negative global economic processes, “Grindeks” concentrates more and more on
the diversification of its business; the participation in the exhibition is a
purposeful marketing project, and in the future we will be able to speak of
specific results.”
This year the “CPhI Worldwide 2009” exhibition has been extensively visited -
approximately 1000 companies from 125 countries of the world have taken part
therein. In comparison with the previous year, less activity has been observed
at the exhibition; however, with each year, the preparation to the exhibition
takes place on more and more professional level, both on the part of organizers
and participants. Well before the exhibition, the participants are offered wide
opportunities on advertising, both in internet and in specialized catalogues,
which allows to evaluate potential cooperation partners in advance, to invite
them to a meeting at the exhibition and to go there already with a specific
aim.
The participation of “Grindeks” at the exhibition has been co-financed by the
European Regional Development Fund.
About “Grindeks”
“Grindeks” is the leading pharmaceutical company in the Baltic States. The main
directions of its operation are research, development, manufacturing and sales
of original products, as well as generics and active pharmaceutical
ingredients. “Grindeks” specializes in the heart and cardiovascular,
psychotropic and anti-cancer therapeutic groups of medications.
„Grindeks” concern consists of four subsidiary companies in Latvia, Estonia and
Russia; as well as representatives and representative offices in 14 countries.
Products of the company are exported to more than 40 countries and its export
comprises more than 96% of the total turnover. The main markets are the Baltic
States, Russia and other CIS countries, as well as Japan and USA. The shares of
JSC „Grindeks” are listed in the Official List of „NASDAQ OMX Riga”.
Further information:
Laila Kļaviņa
Head of the Communications Department
JSC „Grindeks”
E-mail: laila.klavina@grindeks.lv
Phones: +371 67083370, +371 29256012